Described are methods of detecting modified nucleotide bases in a nucleic acid sample using specific DNA glycosylases to excise a modified nucleobase of interest. Prior to glycosylase treatment, DNA target fragment templates are copied by a DNA polymerase to produce a first complementary copy strand that preserves the genetic information of the DNA target fragment. Following glycosylase treatment, the DNA target fragment templates are copied by an abasic bypass polymerase to produce a second complementary copy strand that preserves the epigenetic information of the DNA target fragment. Comparison of the DNA sequences of the two complementary copy strands enables identification of the positions of the modified nucleobases in the DNA target fragment.
Detection of abnormality in specimen image A computer-implemented method of detecting the presence of morphologically abnormal cells in a specimen image comprises: receiving electronic image data representative of a specimen image, the specimen image depicting a plurality of cells; applying an analytical model to each of a plurality of subsets of the image data, each subset corresponding to a respective portion of the specimen image which depicts a single cell, the analytical model configured to output, for each subset of the image data: a value parameterizing a property of the cell; and either a confidence score or an uncertainty score associated with the value, thereby generating output data comprising the plurality of confidence scores or plurality of uncertainty scores; and determining, based on the output data, whether one or more morphologically abnormal cells are likely to be present in the specimen image.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
3.
FILTRATION SYSTEM, METHOD FOR PREDICTING A MAINTENANCE CONDITION OF THE FILTRATION SYSTEM AND METHOD FOR PREDICTING A RECOVERY CONDITION OF THE FILTRATION SYSTEM
A method for predicting a maintenance condition of a filtration system of a diagnostic apparatus or a laboratory analyser at a given time is done by performing the following steps. First a plurality of successive raw permeability values of the permeability of a fluid through the filtration device over a specified measurement period is measured. Then smoothed permeability values are determined by means of a data processing method to reduce the fluctuations of the raw permeability values over time. Afterwards a regression analysis function is applied through the successive permeability values, wherein the regression analysis function comprises fitting parameters being adapted so that the fitting function is fitted to the measured permeability values. Finally, the time, when the regression analysis function will cross a predetermined threshold value is determined, wherein the crossing of the threshold value is judged as a maintenance condition.
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises: a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128); b) at least one sample recognition step comprising localizing at least one sample re- gion on the reflective target (128); and c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser ir- radiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser de- sorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
H01J 49/00 - Spectromètres pour particules ou tubes séparateurs de particules
H01J 49/16 - Sources d'ions; Canons à ions utilisant une ionisation de surface, p.ex. émission thermo-ionique ou photo-électrique
H01J 49/04 - Dispositions pour introduire ou extraire les échantillons devant être analysés, p.ex. fermetures étanches au vide; Dispositions pour le réglage externe des composants électronoptiques ou ionoptiques
Computer-implemented methods for analysing a medical image are provided, the method comprising: obtaining a medical image; inputting the image into a machine learning model, the machine learning model trained with training medical images, by: obtaining a plurality of smaller image segments from the training medical images; obtaining an image embedding for each image segment; and processing the embeddings using one or more attention mechanisms comprising a B-cos transform. Related methods, products and systems are described.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
An in-vitro diagnostic (IVD) analyzer (200) comprising at least one sensor (212) located in a flow-through sensor path (211) of detecting unit and requiring at least one oxygenated calibration fluid (221', 222') for calibration is herein disclosed. The IVD analyzer (200) further comprises a fluid-supply unit (220) comprising at least one deoxygenated calibration fluid (221, 222), a fluid-selection valve (230) and at least one oxygenation tubing (215, 216) having two ends connected to the fluid-selection valve (230) as a loop, wherein the oxygenation tubing (215, 216) comprises oxygen-permeable walls, and wherein the IVD analyzer (200) further comprises a pump (240) and a controller (250) configured to control the pump (240) and the fluid-selection valve (230) for transporting deoxygenated calibration fluid (221, 222) into the oxygenation tubing (215, 216), to wait a predetermined time required for oxygenation of the deoxygenated calibration fluid (221, 222) via oxygen uptake from ambient air through the tubing walls, and to transport the thereby obtained oxygenated calibration fluid (221', 222') into the sensor path (211) for calibration of the at least one sensor (212). A respective automatic method of calibrating at least one sensor (212) is herein also disclosed.
C12Q 1/00 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions
G01N 33/96 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir un étalon de contrôle du sang ou du sérum
Computer-implemented methods of providing a disease diagnosis or prognosis for a patient are described. These comprise generating individual networks, each individual network comprising a plurality of nodes and edges between pairs of the nodes, wherein each node is indicative of a biological factor in biological data for an individual, and each edge is indicative of a relationship between a pair of biological factors corresponding to the nodes that the edge connects for the respective individual; determining the value of one or more similarity metrics between one or more individual networks generated for the patient and one or more individual networks generated for other individuals in the plurality of individuals; and predicting a diagnosis or prognosis for the patient using a machine learning model that takes as input the values of one or more similarity metrics.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Reagents for use in scientific apparatus for chemical or biological analysis; Biochemicals namely, polypeptides for in vitro research use; Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Reagents for in-vitro laboratory use [other than for medical or veterinary purposes]; Chemical reagents for use in genetic research; Chemical preparations for use in dna analysis [other than medical]. In vitro diagnostic preparations for medical use; Biochemical preparations for medical use; Diagnostic reagents for medical use; Reagents for use in medical genetic testing; Reagents for in-vitro laboratory use [for medical purposes]; Chemical preparations for use in dna analysis [medical].
9.
SINGLE MOLECULE MULTI-MOLECULAR TRACE METHODS AND SYSTEMS
Methods of sequencing by expansion and related improvements to the sequencing of surrogate polymers in a nanopore are described. The surrogate polymer is formed from a template nucleic acid molecule. A surrogate polymer includes multiple units. Each unit includes a reporter code portion. The reporter codes correspond to the different nucleotides. surrogate polymers may get stuck in the nanopore. Embodiments described herein address these stuck surrogate polymers. In order to allow for multiple reads on the surrogate polymer, a processive consensus technique can be applied. The surrogate polymer may be moved a few units forward and then fewer units backward so that some of the same reporter codes are identified again. This method allows for multiple reads of the same reporter codes. The surrogate polymer eventually passes through the nanopore in the forward direction. Periodically, higher clearing voltages may be applied to clear any stuck surrogate polymer in the nanopore.
A diagnostic device (110) for monitoring at least one body tissue (134) of a patient is disclosed. The diagnostic device (110) comprises: a. at least one bracelet (112) configured to be strapped around a body part (132) of the patient; b. at least one electromechanical actuator (114) configured for actively varying a circumference of the bracelet (112); c. at least one measurement unit (126) configured for determining at least one item of information on an electrical power applied to the electromechanical actuator (114) and at least one item of circumference information on the circumference of the bracelet (112); and d. at least one evaluation unit (128) configured for determining at least one item of information on a status of the body tissue (134) from the item of information on the electrical power applied to the electromechanical actuator (114) and the item of circumference information, wherein the evaluation unit (128) is configured for determining a point of contact at which the circumference of the bracelet (112) corresponds to the circumference of the body part. Further, a method of monitoring at least one body tissue (134) of a patient is disclosed.
A61B 5/107 - Mesure de dimensions corporelles, p.ex. la taille du corps entier ou de parties de celui-ci
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical preparations for medical purposes; Biological preparations for medical purposes; Biochemical preparations for medical use; In vitro diagnostic preparations for medical use; Diagnostic reagents for medical use; Reagents for in-vitro laboratory use [for medical purposes].. Medical apparatus and instruments; Diagnostic apparatus for medical purposes; Apparatus for carrying-out diagnostic tests for medical purposes; Testing apparatus for medical purposes..
12.
AUTOMATED ANALYSIS DEVICE, AND METHOD FOR OPERATING AUTOMATED ANALYSIS DEVICE
This automated analysis device comprises an analyzing unit 40 for analyzing a sample, and a control device 20 for controlling operations of each mechanism of the analyzing unit 40, wherein the control device 20 calculates a waiting time that a user should wait until the sample or a consumable required to analyze the sample is replaced, on the basis of a time at which the sample or the consumable is to be used last, in an analysis schedule created at a time point at which a replacement request for the sample or the consumable is accepted. By this means, the present invention provides an automated analysis device, and a method for operating the automated analysis device, capable of improving work efficiency.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
13.
IMPROVEMENTS TO NEXT-GENERATION TARGET ENRICHMENT PERFORMANCE
The present disclosure is directed to compositions and kits for PCR amplification. The present disclosure is also directed to methods of amplifying nucleic acid molecules to improve upon uniformity of coverage and/or to reduce GC bias during downstream sequencing operations.
C12Q 1/6806 - Préparation d’acides nucléiques pour analyse, p.ex. pour test de réaction en chaîne par polymérase [PCR]
C12Q 1/6848 - Réactions d’amplification d’acides nucléiques caracterisées par les moyens d’empêcher la contamination ou d’augmenter la spécificité ou la sensibilité d’une réaction d’amplification
14.
COMPOSITIONS AND METHODS FOR DETECTING MONKEYPOX VIRUS
Methods for the rapid detection of the presence or absence of Monkeypox Virus (MPXV) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the MPXV F3L gene and the MPXV B21R gene, along with kits are provided that are designed for the detection of MPXV.
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
The present invention provides a method comprising the steps of a) providing a nucleic acid comprising 5fC, 5hmC, or 5caC, b) providing one reactant comprising two reactive groups wherein the first reactive group is capable of reacting with the formyl hydroxymethyl or carboxyl group, and the second reactive group is a nucleophilic group, c) reacting said first reactive group with the formyl, hydroxymethyl or carboxyl group thereby resulting in a modified 5fC, 5hmC, or 5caC, d) reacting said second reactive group with the C6 position of said modified 5fC, 5hmC, or 5caC, thereby obtaining a bicyclic or tricyclic molecule comprising a 5,6-di-hydro Cytosine entity, and e) deaminating said 5,6-di-hydro Cytosine entity to a 5,6 di-hydro-Uracil entity.
A biomedical knowledge graph system, the system including a computer database of records, the records comprising nodes of biomedical entities and connections between the entities representing biomedical relationships. One or more processors are programmed and configured to extract data from a plurality of data sources, determine biomedical entities and relationships between the entities based on analyzing the data, wherein analyzing the data comprises searching for predetermined identifiers or patterns in the data. Based on the determined biomedical entities, assigning each biomedical entity to a cluster of biomedical entity types. The one or more processors are configured to identify a context for each of the identified biomedical entities based on the assigned cluster and based on elements of the expression of the biomedical data within which the entity is expressed. Based on the identified context and type of the biomedical entity, incorporating records of nodes and connections between nodes into the knowledge graph, the nodes representing biomedical entities and the connections representing biomedical relationships between the entities structured according to the predefined schema.
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer-implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Leukotriene A4 Hydrolase (LTA4H) in a sample of the subject.
G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines
18.
METEORIN-LIKE PROTEIN (METRNL) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Meteorin-like protein (METRNL) in a sample of the subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
19.
FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1 (FGFBP1) AS (BLOOD) BIOMARKER FOR THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for assessing whether a subject has Polycystic Ovarian Syndrome (PCOS) or is at risk of developing PCOS, to a method of selecting a patient for therapy of PCOS, to a method for monitoring PCOS progression or for monitoring response to treatment and to a computer- implemented method for assessing a subject with suspected PCOS, by determining the amount or concentration of Fibroblast Growth Factor-Binding Protein 1 (FGFBP1) in a sample of the subject.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
20.
RATIO BETWEEN LTA4H AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total LTA4H in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentration determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
G01N 33/88 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des prostaglandines
21.
RATIO BETWEEN FGFBP1 AND METRNL IN THE ASSESSMENT OF POLYCYSTIC OVARIAN SYNDROME
The present invention relates to a method for diagnosing Polycystic Ovarian Syndrome (PCOS) in a subject, said method comprising the steps of a) determining the amount or concentration of total FGFBP1 in sample from the subject, b) determining the amount or concentration of METRNL in a sample from the subject, c) calculating a score of the amounts or concentrations determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing PCOS in a subject.
G01N 33/563 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet faisant intervenir des fragments d'anticorps
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
22.
METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM
The disclosure refers to a method of operating a laboratory sample distribution system having a plurality of carriers (4) configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) assigned to the laboratory devices (3) and providing support to the plurality of carriers (4); and a driving device (13) configured to move, in response to driving control signals, the plurality of carriers (4) between plane positions (5) provided on the transport plane (1). The method comprises: prior to moving the carriers (4) on the transport plane (1), pre-determining off-line routes (6) on the transport plane (1) by one or more processors of a data processing device, the pre-determining comprising: determining a model representing the transport plane (1) with plane locations (5') and location-to-location movements between plane locations (5') associated to the plurality of carriers (4) calculating an optimized set of off-line routes between pairs of plane locations from the plurality of plane locations (5') using the model, the calculating comprising solving an optimization problem in which routes between the pairs of plane locations are simultaneously optimized; and providing the optimized set of off-line routes as off-line routes (6) on the transport plane (1); and controlling the driving device (13) such that the carriers (4) are moved along the pre-determined off-line routes (6) on the transport plane (1). Furthermore, a laboratory sample distribution system, and a laboratory automation system are provided.
G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
23.
METHOD OF OPERATING A LABORATORY SAMPLE DISTRIBUTION SYSTEM, LABORATORY SAMPLE DISTRIBUTION SYSTEM, AND LABORATORY AUTOMATION SYSTEM
The disclosure refers to a method of operating a laboratory sample distribution system having: a plurality of carriers (4) having a number of n (n>3) carriers (4) each configured to carry one or more sample containers containing a sample to be analyzed by laboratory devices (3); a transport plane (1) configured to support to the plurality of carriers (4), wherein the transport plane (1) comprises a plurality of interconnected transport modules comprising a plurality of plane fields (5); and a driving device (13) configured to control movement of the plurality of carriers (4) along individual routes between the plurality of plane fields (5). The method com- prises: moving the plurality of carriers (4) along the individual routes on the transport plane (1), wherein the moving, for each carrier, comprises executing at least once steps of reserving a route segment along the individual route, the route segment being provided by one or more plane fields of the plurality of plane fields (5), and moving the carrier (4) along the route seg- ment; and preventing, for the plurality of carriers (4), a deadlock arrangement on the transport plane in which the plurality of carriers (4) block each other from further movement along the individual routes (6). The preventing is further comprising: determining, at a present operation time, a potential deadlock arrangement for the plurality of carriers (4) on the transport plane (1) at a future operation time, wherein the potential deadlock arrangement is assigned a number of n deadlock plane fields occupied by the plurality of carriers (4) in case of the potential dead- lock arrangement; for a first carrier from the plurality of carriers (4) moving along a first individ- ual route, reserving a first route segment ending with a first end plane field; and assigning a non-reserve flag to a next plane field which is next to the first end plane field along the first individual route. Further, a laboratory sample distribution system, and a laboratory automation system are provided.
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
G06Q 10/0835 - Relations entre l’expéditeur ou le fournisseur et les transporteurs
B65G 54/02 - Transporteurs non mécaniques, non prévus ailleurs électrostatiques, électriques ou magnétiques
24.
A METHOD FOR QUALITY CHECK OF AT LEAST ONE LC-MS MEASUREMENT
A method for quality check of at least one Liquid Chromatography-Mass Spectrometry (LC-MS) measurement on a sample comprising an analyte of interest and a defined amount of at least one internal standard is proposed. The method comprises the following steps a) (120) determining an information (peakAreaaqn) about an analyte signal and an information (peakAreatqn) about an internal standard signal of the LC-MS measurement; b) (122) determining at least one monitoring parameter by using the information about the analyte signal and the information about the internal standard signal by using at least one processing device (114), wherein the monitoring parameter comprises a minimal limit for the internal standard signal for said analyte signal of said sample; c) (124) comparing the information about the internal standard signal to the monitoring parameter by using the processing device (114), wherein the LC-MS measurement is flagged by using the processing device (114) as to fulfil the quality check in case the information about the internal standard signal is greater or equal to the monitoring parameter or otherwise as failed.
The present disclosure provides a method for enrichment of at least one target nucleic acid in a library of nucleic acids. This present disclosure is also directed to a faster and easier method of target capture using primer extension reactions that can improve ease of use, turnaround time, and variant allele specificity by designing target enrichment primers to specifically enrich library fragments based on the relative location of the variant base(s) in the primer, the utilization of polymerases with better priming specificity, designing the variant bases in the capture primer, designing the variant bases in the release primer, and/or designing variant specific primers to the both the plus and minus strands of the target library fragment.
A door mechanism device (110) for a door (100) for a transport apparatus (500) for trans- porting a sample container carrier is disclosed. The door mechanism device (110) comprises at least a first fixation bracket (112) configured for mounting the door mechanism device (110) to a frame of the transport apparatus, at least a first upper lever (114), at least a first lower lever (116), at least a first door mount (120) configured to be mounted to a cover (102) of a door (100) of the transport apparatus. The first upper lever (114) and the first lower lever (116) are rotatably mounted to the first fixation bracket (112) and the first door mount (120). The first upper lever (114) and the first lower lever (116) are rotatable around lever axes (122) such that the first door mount (120) is movable between a first position and a second position with the first door mount (120) substantially maintaining its orientation within a plane perpendicular to the lever axes (122). Further, a door (100) for a transport apparatus for transporting a sample container carrier and a transport apparatus (500) for transporting a sample container carrier are disclosed.
E05D 15/40 - Suspensions pour battants portés par des bras mobiles dans des plans verticaux
E05D 15/46 - Suspensions pour battants portés par des bras mobiles dans des plans verticaux à deux couples de bras pivotants
E05F 5/00 - Dispositifs de freinage, p.ex. ralentisseurs; Butées; Tampons
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
The present disclosure relates, in general, to novel and easily accessible fluorescent compounds with large Stokes shift (LSS) and thermostable fluorescence for expanding the multiplexing capabilities of fluorescence-based nucleic acid detection technologies. Moreover, conjugates, probes and FRET pairs comprising these fluorescent compounds as well as methods for amplification and detection of a target nucleic acid utilizing these fluorescent compounds and methods of labeling are also provided.
C09B 11/24 - Phtaléines contenant des groupes amine
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
A method of operating a distribution system (110), wherein the distribution system (110) comprises - a number of carriers (112) configured for carrying one or more objects (114), - a transport plane (122) configured for supporting the carriers (112), wherein the transport plane (122) comprises a plurality of transport modules (124), wherein a grid (126) of logical positions (128) is defined on the transport plane (122), - a drive system (130) configured for moving the carriers (112) on the transport plane (122) between the logical positions (128), - a control system (136) configured for controlling the drive system (130), wherein the control system (136) comprises a routing system (138) configured for calculating routes for the carriers (112), wherein the method comprises the steps: a) defining a global pattern of safe points (148) and applying the global pattern on the transport plane (122) by using the routing system (138), wherein safe points (148) are logical positions (128) selected in view of a range of motion for a carrier (112) occupying said logical position (128) such that on the safe points (148) a carrier (112) can be placed and can be moved away again, wherein the global pattern is applied onto the transport plane (122) independently of module boundaries; b) calculating partial routes for the carriers (112) so that an end position of each partial route is either one of the safe points (148) or has a free path to one of the safe points (148) to be reachable in the next partial route by using the routing system (138). Further, a distribution system (110) and a computer program and a computer-readable storage medium for performing the method according to the present invention are disclosed.
G01N 15/04 - Recherche de la sédimentation des suspensions de particules
B65G 35/06 - Transporteurs mécaniques non prévus ailleurs comportant un porte-charges se déplaçant le long d'un circuit, p.ex. d'un circuit fermé, et adapté pour venir en prise avec l'un quelconque des éléments de traction espacés le long du circuit
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
G06Q 10/08 - Logistique, p.ex. entreposage, chargement ou distribution; Gestion d’inventaires ou de stocks
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
The present disclosure relates, in general, to the methods for the rapid detection of the presence or absence of Lymphogranuloma Venereum (LGV)-causing serovars of Chlamydia trachomatis in a biological or non-biological sample. The methods can include performing an amplification step, a hybridization step, and a detection step. Furthermore, oligonucleotide primers and probes targeting the pmpH gene for the L serovars of Chlamydia trachomatis, along with kits are provided that are designed for the detection of L serovars.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
30.
DISTRIBUTION SYSTEM AND METHOD FOR DISTRIBUTING A PLURALITY OF CARRIERS
A distribution system (110) and a method for distributing a plurality of carriers (114) using the distribution system (110) are disclosed. The distribution system (110) comprises: - at least one transport plane (118) comprising logical positions (120); - a plurality of carriers (114) for transporting objects (122); - at least one drive system (126) for moving the carriers (114) on the transport plane (118) between the logical positions (120); and - at least one control system (128) configured for controlling the carriers (114) to move on a planned route from a start position to a final destination position on the transport plane (118), wherein the planned route comprises partial routes (144), wherein the control system (128) comprises at least one routing system (130) configured for calculating routing plans for carriers (114) on the transport plane (118) by modeling the transport plane (118) with graph of nodes (132), wherein the routing system (130) is configured for calculating the routing plans considering moving time periods (160) and waiting time periods (162), wherein the routing system (130) is configured for assigning waiting time periods (162) for carriers (114) depending on a reservation of logical positions (120) of the partial routes (144) of other carriers (114), wherein, if a carrier (114) experiences a time delay (158) during execution of a move, the routing system (130) is configured for shifting the experienced time delay (158) to at least one upcoming waiting time period (166) of a carrier (114).
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
B65G 35/06 - Transporteurs mécaniques non prévus ailleurs comportant un porte-charges se déplaçant le long d'un circuit, p.ex. d'un circuit fermé, et adapté pour venir en prise avec l'un quelconque des éléments de traction espacés le long du circuit
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
G06Q 10/08 - Logistique, p.ex. entreposage, chargement ou distribution; Gestion d’inventaires ou de stocks
31.
METHOD FOR DIAGNOSING ENDOMETRIOSIS AND FOR CLASSIFYING THE STAGE OF ENDOMETRIOSIS
The present invention relates to methods of diagnosing whether a subject has endometriosis, to methods of classifying the stage of endometriosis, to methods of determining the therapeutic effect of a treatment regimen for endometriosis, and methods of monitoring endometriosis progression in a subject, by determining the amount or concentration of c-Kit in a sample of the subject, and comparing the determined level to a reference value.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
The invention includes improved methods and compositions for reduction of a C5-C6 double bond of a cytosine. In particular, the improved methods and compositions for reduction of a C5-C6 double bond of a cytosine is via enzymatic means, not via chemical means. In particular, the disclosure is directed to methods of converting 5,6-dihydro-fC (fC) and/or 5,6-dihydro-caC to 5,6-dihydro-U (DHU). In particular, the disclosure is directed to methods of converting 5fC and/or 5caC to DHU. In addition, the disclosure is directed to methods for detection of epigenetic cytosine modification, particularly cytosine methylation, using ene reductases to reduce the C5-C6 double bond of cytosine.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Laboratory instruments for use in research and science; laboratory instruments for research diagnostic purposes; apparatus for pre-analytical treatment for scientific purposes; laboratory equipment, namely automated sample handling equipment; computer hardware and software for medical and diagnostic purposes; computer software for the provision of automated diagnostic laboratory processes; computer software and hardware for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management.. Analyzers for in-vitro diagnostic testing for medical purposes; laboratory apparatus for medical and diagnostic purposes; apparatus for pre-analytical treatment for medical purposes..
09 - Appareils et instruments scientifiques et électriques
Produits et services
Computer software for use in the field of healthcare;
computer software for medical and diagnostic purposes;
computer software for the provision of automated diagnostic
laboratory processes; computer software for use with
laboratory instruments, namely, for use in providing remote
automated control, connection, data analysis, and data
management; computer systems and software for collecting,
storing, analyzing and reporting biological information, and
for sample tracking and managing projects, laboratory
workflow and data, for use in the fields of scientific,
diagnostic and clinical research and for clinical diagnostic
purposes.
35.
FERROCENE LABELLED PRIMERS FOR ELECTROCHEMICAL DETECTION
The present invention provides novel primers in which a ferrocene label is attached to the primer. The ferrocene label is incorporated into the amplification product. When the amplification product incorporating the ferrocene label is denatured, it can bind to a capture probe and the presence or absence of the ferrocene label can be detected via electrochemical detection. The system avoids the use of a signal probe in a sandwich assay as historically used during electrochemical detection.
A method for multiple reaction monitoring using a mass spectrometry device (106) is proposed. The method comprises the following steps: i) (128) measuring, by using the mass spectrometry device (106), multiple reaction monitoring transitions of quantifier and qualifier of both an internal standard and an analyte using staggered- multiple reaction monitoring, wherein the staggered-multiple reaction monitoring comprises at least three multiple reaction monitoring channel groups, wherein one of the multiple reaction monitoring channel groups measure at respective theoretical m/z values of the quantifier and qualifier of both the internal standard and the analyte and the two other multiple reaction monitoring channel groups measure at respective m/z values shifted to higher and lower values by a predefined level; ii) (130) comparing, for at least two groups, at least two of the quantifier/qualifier ratios of the multiple reaction monitoring transitions of the internal standard with a reference value from a database (126) by using at least one processing device (120), wherein the comparison comprises determining a deviation between the quantifier/qualifier ratios and the reference value; iii) (132) determining from the analyte and the internal standard measured multiple reaction monitoring transitions a measurement result by using the processing device (120), if the deviation for at least one of the quantifier/qualifier ratios is within at least one predefined tolerance range, otherwise rejecting (136) the measured multiple reaction monitoring transitions.
A computer-implemented method, system and decision support system adapted to provide arterial venous blood gas values without the provision of an arterial oxygenation saturation value or arterial blood gas values. The method comprises the provision of arterial blood gas values from a subject, for which said subject, only venous blood gas values are provided, by providing a mathematical model adapted to convert said venous blood gas values with a provided predefined default arterial oxygenation value to output arterial blood gas values of said subject. The present invention thus provides a method for providing arterial blood gas values from a specific subject without the need of providing an arterial blood sample from a painful arterial blood draw or the need for an arterial oxygenation saturation value of the subject, thus reducing distress to said patient and a reduction of tasks to relevant health care personnel.
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p.ex. de la concentration des gaz dans le sang, de la valeur du pH du sang
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
The present invention concerns the field of re-usable immunosensors. In particular, it relates to a method for regenerating an immunosensor comprising at least one polypeptide attached to an electroconductive surface of said immunosensor, wherein the at least one polypeptide is capable of specifically binding an analyte to be detected by the immunosensor, said method comprising the step of applying to the immunosensor at a temperature selected from the temperature range from about 35°C to about 42°C a positive electrical potential of about 0.3 V on said electroconductive surface of the immunosensor for a time sufficient to allow regeneration. Moreover, it also relates to a regenerated immunosensor obtainable by the method of the present invention and a system and device comprising the immunosensor as described herein, wherein said device is capable of applying a positive electrical potential of about 0.3 V on said electro conductive surface of the immunosensor for a time sufficient to allow regeneration. The present invention also contemplates, in general, the use of a temperature selected from the temperature range from about 35°C to about 42°C and a positive electrical potential of about 0.3 V on an electro conductive surface of an immunosensor as described in any one of claims 1 to 13 for regeneration of said immunosensor.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemical, biological and biochemical preparations for scientific and research purposes; chemical preparations for analysis in laboratories; chemical substances for analyses in laboratories, other than for medical or veterinary purposes..
40.
High Affinity Antibodies Specifically Binding to α-1,6-Core-Fucosylated Alpha-Fetoprotein
The present invention relates to monoclonal antibodies and antigen binding fragments that specifically bind to α-1,6-core-fucosylated alpha-fetoprotein (AFP), which is the core component of AFP-L3. Thus, the antibodies and antigen binding fragments provided herein may also be referred to as AFP-L3 antibodies. Also provided are polynucleotides encoding the antibodies or antigen binding fragments of the invention, host cells expressing the antibodies and antigen binding fragments of the invention, methods for producing the antibodies and antigen binding fragments of the invention, and uses of the antibodies and antigen binding fragments of the invention. Also provided herein is a pretreatment agent facilitating the binding of the antibodies and antigen binding fragments of the invention to α-1,6-core-fucosylated AFP. The present invention further relates to kits comprising the antibodies and antigen binding fragments of the invention and optionally the pretreatment agent of the invention.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Computer software for use in the field of healthcare; computer software for medical and diagnostic purposes; computer software for the provision of automated diagnostic laboratory processes; computer software for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management; computer systems and software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes.
42.
METHOD FOR OPERATING A SORTER DEVICE IN AN IVD LABORATORY SYSTEM AND IVD LABORATORY SYSTEM
The present disclosure refers to a method for operating a sorter device (5) in an IVD laboratory system, the method comprising providing a sorter device (5) in an IVD laboratory system (1) provided with a system operation controller (3), the sorter device (5) having a plurality of sample container racks each provided with reception holes for receiving sample containers (4), a handling device configured to pick sample containers (4) from and place sample containers (4) in the reception holes of the sample container racks, a sorter device controller configured to control operation of the sorter device (5) and connectable to the system operation controller (3), and an output device functionally connected to the sorter device controller and configured to output at least one of audio data and video data. The sorter device (5) is configured in a pre-operation process, the configuring comprising: assigning the plurality of sample container racks to a plurality of processing sub-targets conducted by the IVD laboratory system (1) in operation, wherein a first sample container rack is assigned to a first processing sub-target and a second sample container rack is assigned to a second processing sub-target which is different from the first processing sub- target, and assigning to the first sample container rack a first threshold value indicative of a first threshold number of sample containers (4) in the first sample container rack, wherein the first threshold number of sample containers (4) is smaller than a maximum number of sample containers (4) receivable in the first sample container rack. The sorter device (5) is operated in an operation process, the operating comprising: placing sample containers (4) in the reception holes of the first sample container rack by the handling device, determining a first present number of sample containers (4) received in the first sample container rack by the sorter device controller, comparing the first present number of sample containers (4) to the first threshold value by the sorter device controller, and if the first present number of sample containers (4) is equal to or greater than the first threshold value, outputting a first warning data through the output device. Furthermore, an IVD laboratory system (1) is provided.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
43.
METHOD FOR DETERMINING A DILUTION FACTOR OF A SAMPLE
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p.ex. dispositifs d'aspiration, dispositifs d'injection
G01N 1/38 - Dilution, dispersion ou mélange des échantillons
The present invention relates to a method for determining a lactone analyte in a sample, comprising (i) contacting said sample with a derivatization reagent comprising a nucleophilic reagent; (ii) determining a nucleophilic reagent-derivative of said lactone analyte obtained in step (i), and (iii) determining said lactone analyte based on the determination of the nucleophilic reagent-derivative of said lactone analyte in step (ii). The present invention also relates to methods uses, compounds, kits and devices related thereto.
G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques
A method for autonomous teach-in of at least one target position of a supply device (120) of a slide imaging apparatus (110) is disclosed. The slide imaging apparatus (110) comprises at least one imaging device (126, 128) configured to generate an image of a sample mounted on a slide (140). The target position is a position on the imaging device (126, 128). The slide imaging apparatus (110) comprises at least one operating system (170) configured for controlling operation of the supply device (120). The method comprises the following steps i) (186) providing at least six pre-defined positions by using the operating system (170); ii) (188) driving the supply device (120) to the six pre-defined positions until colliding with the imaging device (126, 128) by using the operating system (170) and detecting collisions with the imaging device (126, 128); iii) (190) evaluating the detected collisions by using the operating system (170), thereby determining the target position.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G05B 19/425 - Apprentissage de positions successives par commande numérique, c.à d. des commandes étant introduites pour commander l'asservissement en position de la tête porte-outil ou de l'effecteur de bout de bras
B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p.ex. à la vue ou au toucher
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
46.
METHOD FOR ESTABLISHING METROLOGICAL TRACEABILITY FOR AT LEAST ONE IN VITRO DIAGNOSTIC MEDICAL DEVICE
ƒpp cƒpp PP ≥ 1. In each adjustment step a signal adjustment function or a concentration adjustment function is determined and at least one target concentration value is assigned.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
47.
METHOD AND LABORATORY SYSTEM FOR DETERMINING AT LEAST ONE CONTAINER INFORMATION ABOUT A LABORATORY SAMPLE CONTAINER
The invention relates to a method for determining at least one container information (coi) about a laboratory sample container (1), wherein the method comprises the steps: a) acquiring an image (ibc) comprising a brightness and/or color information (bci) of a possible region (2) of the container (1), b) acquiring a map (md) comprising a depth information (di) of the region (2), and c) determining the container information (coi) by fusing the brightness and/or color information (bci) and the depth information (di).
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
The invention relates to novel HIV gp41 antigen compositions that are suitable for detecting antibodies against HIV in an isolated biological sample providing high specificity immunoassay results. It further relates to methods detecting HIV antibodies, use of novel HIV gp41 antigen compositions in immunoassays as well as to reagent kits comprising novel HIV gp41 antigen compositions.
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
49.
COMPOSITIONS AND METHODS THAT REDUCE PRUSSIAN BLUE FORMATION DURING NANOPORE SEQUENCING
This application discloses electrochemical cells, nanopore devices, and associated buffer compositions useful for nanopore-based nucleic acid sequencing. Also disclosed are methods for using the electrochemical cells, devices, and compositions in nanopore-based nucleic acid sequencing methods, such as nanopore Sequencing-by-Expansion (Nano-SBX) and nanopore Sequencing-by-Synthesis (Nano-SBS) methods.
A position tracking system (112) for tracking a relative position between at least two connected modules (114) is disclosed. The position tracking system (112) comprises: - at least one target (118) associated with a first one of the at least two connected modules (114), wherein the at least one target (118) is at least one of arrangeable on and arrangeable within the first one of the at least two connected modules (114), wherein the at least two connected module (114) are mechanically interacting entities and/or components, configured for allowing transport of objects from one module to the other module; - at least one position sensor (120) associated with a second one of the at least two connected modules (114), wherein the position sensor (120) is configured for generating at least one sensor signal according to a relative position between the at least one position sensor (120) and the at least one target (118), wherein the at least one position sensor (120) is at least one of arrangeable on and arrangeable within the second one of the at least two connected modules (114); - at least one processing unit (122) configured for tracking a relative position between the connected modules (114) from the at least one sensor signal in at least one plane (124); and - at least one further sensor (140) configured for generating a further sensor signal according to at least one further parameter, wherein the further sensor (140) is selected from the group consisting of: a temperature sensor (142) and/or a humidity sensor, wherein the processing unit (122) is further configured for considering the at least one further sensor signal when determining the relative position between the connected modules (114). Further disclosed are a monitoring system (110) for monitoring at least two connected modules (114), method for tracking a relative position between at least two connected modules (114) by using at least one position tracking system (112) and a method for monitoring at least two connected modules (114) by using at least one monitoring system (110).
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
51.
GLYCAN STRUCTURES OF HAPTOGLOBIN AS A BIOMARKER OF HEPATOCELLULAR CARCINOMA
The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject comprising determining the amount of one or more glycan structure at position N207 of haptoglobin (i.e. of the B-chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject. Also disclosed are a glycan structure as well as a glycopeptide comprising said glycan structure, both of great utility in the detection of HCC. Further, the present invention relates to the use of one or more glycan structure at position N207 or of a glycopeptide comprising N207 of haptoglobin in combination with AFP and/or PIVKA in the detection of HCC.
A method of separating stereoisomers of N-phthaloyl-glutamic acid is described. The method comprises passing a solution comprising an L/D stereoisomer mixture of N-phthaloyl-glutamic acid through a chiral chromatography column by normal phase chromatography, wherein the chiral chromatography column comprises, as a stationary phase, silica having groups represented by formula (1) as described herein covalently bonded to a surface thereof.
B01D 15/32 - Chromatographie en phase liée, p.ex. avec une phase normale liée, une phase inverse ou une interaction hydrophobe
B01D 15/38 - Adsorption sélective, p.ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction spécifique non couverte par un ou plusieurs des groupes , p.ex. chromatographie d'affinité, chromatographie d'échange par ligand ou chromatographie chirale
B01J 20/24 - Composés macromoléculaires d'origine naturelle, p.ex. acides humiques ou leurs dérivés
The present invention relates to in vitro methods for aiding in the detection of hepatocellular carcinoma (HCC) in a subject. The method may comprise determining the amount of one or more N-glycan structure attached to haptoglobin (i.e. of the β- chain of haptoglobin having the sequence given in SEQ ID NO: 1) in a sample obtained from said subject and comparing the amount of said one or more glycan structure to a reference amount of said one or more glycan structure, wherein an altered amount of said one or more glycan structure in said patient sample relative to the reference amount of said one or more glycan structure is indicative for HCC. Further, the present invention relates to the use of one or more glycan structure attached to haptoglobinor of a glycopeptide derived from haptoglobin in combination with AFP and/or PIVKA-II in the detection of HCC.
Techniques described herein include, for example, generating a feature map for an input image, generating a plurality of concentric crops of the feature map, and generating an output vector that represents a characteristic of a structure depicted in a center region of the input image using the plurality of concentric crops. Generating the output vector may include, for example, aggregating sets of output features generated from the plurality of concentric crops, and several methods of aggregating are described. Applications to classification of a structure depicted in the center region of the input image are also described.
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p.ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersections; Analyse de connectivité, p.ex. de composantes connectées
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
chemical, biochemical and biological reagents for scientific and research purposes; kits consisting primarily of reagents and diagnostic preparations for research purposes medical diagnostic reagents and assays for the analysis of biological samples; diagnostic kits consisting primarily of medical diagnostic reagents and preparations for the analysis of biological samples for medical diagnostic purposes and also including printed instruction sheets
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
Produits et services
chemical, biological and biochemical preparations for scientific and research purposes, namely, diagnostic and detection reagents for scientific and research purposes; in vitro diagnostic reagents for use in industry and science; chemical preparations for use in science, namely, chromatography; separation materials for use in liquid chromatography columns, namely, chromatography separation media for separation of a mixture into components; chemical reagents for scientific purposes, namely, use with spectrometers for analyzing biological samples in the clinical diagnostic field Chemical, biological and biochemical preparations for medical purposes; namely, diagnostic and detection reagents for medical use; in vitro diagnostic reagents for clinical medical or medical use; in vitro diagnostic agents for medical use, namely, reagents and control solutions for analysis of biological samples for medical diagnostic purposes Laboratory instruments for use in preparation of biological samples, chromatography and analysis of biological samples, namely, chromatography apparatus for laboratory use; scientific apparatus, namely, spectrometers; chromatography columns for laboratory use with laboratory instruments for use in preparation of biological samples, chromatography and analysis of biological samples; downloadable computer software for use in the field of diagnostics, namely, software for storage, retrieval, and processing of mass spectrometry data; downloadable computer software featuring algorithms for laboratory test data analysis; downloadable computer software having processing algorithm used to identify, filter, analyze, visualize and manage data from biological information
57.
SYSTEMS AND METHODS FOR PREDICTING COVID-19 CASES AND DEATHS
A machine learning and/or deep learning framework was constructed and used to forecast COVID-19 cases and deaths. Multiple open data sources relevant for the pandemic evolution in a geographic area, such as the United States or another country or region, can be processed to extract a plurality of features, such as localized (i.e., county level, city level, regional level, province level, etc.) COVID cases and deaths, demographics and socioeconomic factors, non- medical interventions, and mobility (i.e., from cell phone and/or GPS data).
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p.ex. de la grippe
58.
METHODS FOR MANAGEMENT OF PROSTATE CANCER BASED ON PSA GLYCOSYLATION
The present invention relates to methods for assessing whether or not a patient has aggressive prostate cancer by determining the levels of particular glycoforms attached to prostate specific antigen (PSA) protein in a biofluid sample of a subject, and comparing the determined level or concentration to a reference. The methods are particularly useful for assessing subjects that have 2-10 ng/ml total PSA in the subject's serum.
The present disclosure relates to a process for the regiochemically and enantiomerically controlled synthesis of phosphoramidite-containing monomers, and to intermediate products of this process. In some embodiments, the phosphoramidite-containing monomers or their precursors are regioisomerically and/or enantiomerically pure and may be polymerized into polymers or copolymers.
Disclosed herein are techniques for facilitating a clinical decision for a patient based on identifying a group of patients having similar attributes as the patient. The group of patients can be identified using information from a predictive machine learning model that performs a clinical prediction for the patient. At least some of the attributes of the group of patients can be output to support a clinical decision. The attributes may include, for example, biography data of the patient, results of one or more laboratory tests of the patient, biopsy image data of the patient, molecular biomarkers of the patient, a tumor site of the patient, and a tumor stage of the patient.
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p.ex. pour des dossiers électroniques de patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes]. Medical apparatus and instruments; diagnostic apparatus for
medical purposes; apparatus for carrying-out diagnostic
tests for medical purposes; testing apparatus for medical
purposes.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Software as a service (SaaS) in relation to medical data and
information; design and development of computer software in
the medical field; provision of non-downloadable computer
software in the medical field; provision of non-downloadable
software for use in clinical decision support and
operational decision support; provision of non-downloadable
software for use in providing health care information;
provision of non-downloadable software for use in capture
and analysis services to improve patient care; providing
temporary use of non-downloadable computer software for use
as programming interfaces (API); cloud computing services;
design and development of databases in the medical field;
technical support services being monitoring of computer
systems for use with medical devices and equipment as well
as clinical facilities with the support of communication
technology, in particular internet technology.
63.
TROPONIN MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being a cardiac Troponin, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being a cardiac Troponin and a second biomarker selected from the group consisting of: a BMP 10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP -type peptide, cardiac myosin binding protein C (cMyBPC) and ANG2 (Angiopoietin 2), or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
64.
CMYBPC MARKER COMBINATIONS FOR EARLY DISCRIMINATION OF TYPE 2 VERSUS TYPE 1 ACUTE MYOCARDIAL INFARCTION
The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10- type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
The present invention includes: a reagent vessel holding part that holds a reagent vessel for accommodating a reagent; a reagent vessel information detection unit that detects information relating to the reagent vessel; a display unit that displays a screen including an operation region where operations from a user are received; and a control unit that causes the display unit to display the screen. The control unit has: a vessel presence/absence determination unit that determines whether the reagent vessel is present in the reagent vessel holding unit on the basis of the information detected by the reagent vessel information detection unit; a first operation region output unit that outputs, to the screen, a first operation region which is operated when the user has confirmed removal of the reagent vessel; a second operation region output unit that outputs, to the screen, a second operation region which is operated when shutdown is performed; and a warning output unit that outputs, to the screen, a warning prompting removal of the reagent vessel when the vessel presence/absence determination unit has determined that the reagent vessel is present. The foregoing makes it possible to provide an automated analysis device which prevents shutdown from starting while a reagent has been left behind.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Chemical preparations for medical purposes; biological
preparations for medical purposes; biochemical preparations
for medical use; in vitro diagnostic preparations for
medical use; diagnostic reagents for medical use; reagents
for in-vitro laboratory use [for medical purposes]. Medical apparatus and instruments; diagnostic apparatus for
medical purposes; apparatus for carrying-out diagnostic
tests for medical purposes; testing apparatus for medical
purposes.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
downloadable computer software programs for medical purposes, namely, for use in operating a diagnostic apparatus for analyzing in-vitro diagnostic tests medical instruments and apparatus, namely, urinalysis diagnostic apparatus for analyzing and evaluating in-vitro diagnostic tests
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Biochemical reagents used for non-medical purposes; buffer
solutions for scientific purposes; chemical reagents for
molecular biology, other than for medical or veterinary use.
70.
METHOD FOR DETECTING AN ANALYTE OF INTEREST IN A SAMPLE
The present invention relates to a method for determining at least one analyte of interest and the use thereof. The present invention further relates to a kit, a complex, a method to synthesize a complex, a monomer and the use thereof for detecting the analyte of interest in the sample.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
The present invention concerns the field of diagnostics. Specifically, it relates to a method for assessing a subject with suspected infection comprising the steps of determining the amount of a first biomarker in a sample of the subject, said first biomarker being DLL1, determining the amount of a second biomarker in a sample of the subject, said second biomarker being GDF15, comparing the amounts of the biomarkers to references for said biomarkers and/or calculating a score for assessing the subject with suspected infection based on the amounts of the biomarkers, and assessing said subject based on the comparison and/or the calculation. The invention also relates to the use of a first biomarker being DLL1 and a second biomarker being GDF15, or a detection agent specifically binding to said first biomarker and a detection agent specifically binding to said second biomarker for assessing a subject with suspected infection. Moreover, the invention further relates to a computer-implemented method for assessing a subject with suspected infection and a device and a kit for assessing a subject with suspected infection.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes
72.
METHOD FOR IMPROVING CROSS-FLOW FILTRATION AND CROSS-FLOW FILTRATION SYSTEM
A method of cross-flow filtering wastewater from a diagnostic apparatus or a laboratory analyser, wherein the wastewater comprises nanoparticles and/or microparticles, and the wastewater is streaming in a laminar flow across a surface of a filter membrane, the method comprising: (a) streaming the wastewater across the surface of the filter membrane with a flow rate, so that the flow of the wastewater is a laminar flow with a Reynolds number (Re) of smaller than 500; (b) streaming the wastewater in pulse cycles across the surface of the filter membrane, wherein each pulse cycle comprises one active phase in which the wastewater is under a duty pressure and one inactive phase in which the wastewater is under an inactive pressure, wherein the inactive pressure is no more than 10% of the duty pressure and the active phases have a duration of greater than 50 % of the corresponding pulse cycles; and (c) separating the nanoparticles and/or microparticles from the wastewater when the wastewater passes through the filter membrane. Also described is a cross-flow filtration system configured for performing the method.
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Software as a service (SaaS) in relation to medical data and information; design and development of computer software in the medical field; provision of non-downloadable computer software in the medical field; provision of non-downloadable software for use in clinical decision support and operational decision support; provision of non-downloadable software for use in providing health care information; provision of non-downloadable software for use in capture and analysis services to improve patient care; providing temporary use of non-downloadable computer software for use as programming interfaces (API); cloud computing services; design and development of databases in the medical field; technical support services being monitoring of computer systems for use with medical devices and equipment as well as clinical facilities with the support of communication technology, in particular internet technology.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biochemical and biological preparations for
scientific and research purposes; chemical reagents for
research or laboratory use, other than for medical or
veterinary use; chemical reagents for the preparation and
staining of tissue specimens for research purposes; chemical
reagents for use in histological and cytological tissue
processing. Chemical, biochemical and biological preparations for
medical purposes; in vitro diagnostic reagents for medical
use; histology and cytology reagents and staining dyes for
preparation and staining of tissue specimens for medical
purposes; Diagnostic reagents for medical use in the fields
of pathology, immunohistochemistry and in
situ-hybridization. Scientific apparatus and instruments; scientific apparatus,
equipment and instruments for performing analyses in
laboratories; laboratory instruments for use in research and
science; laboratory equipment, namely automated sample
handling equipment; diagnostic apparatus and instruments,
namely apparatus for processing, staining and visualization
of tissue or cell-based samples for research or scientific
use; automated processing apparatus and instruments for the
treatment and the automated tissue staining of tissue slide
specimens for research and scientific use; automated
laboratory instruments, namely slide scanners, digital
imagers, microscopes and computer systems for staining and
visualization of tissue or cell based samples for research
and scientific use; computer software for use in the field
of healthcare; computer software for medical and diagnostic
purposes; computer software for the provision of automated
diagnostic laboratory processes; computer software for use
with laboratory instruments, namely, for use in providing
remote automated control, connection, data analysis, and
data management; computer systems and software for
collecting, storing, analyzing and reporting biological
information, and for sample tracking and managing projects,
laboratory workflow and data, for use in the fields of
scientific, diagnostic and clinical research and for
clinical diagnostic purposes; downloadable
bioinformatics-enabled diagnosis software. Medical apparatus and instruments for medical purposes;
diagnostic apparatus for medical purposes; medical apparatus
for performing in-vitro diagnostic tests; automated slide
preparation and staining apparatus for use with tissue slide
specimens for diagnostic use; medical apparatus and
instruments for performing histological and cytological
tissue processing and staining for diagnostic purposes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
(1) Chemical reagents for use in genetic research; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; reagents for scientific purposes for use in nucleic acid isolation and purification
(2) Diagnostic reagents for medical laboratory use; medical diagnostic reagents and assays for testing of body fluids
(3) DNA microarrays for laboratory use; laboratory instrument for the detection of pathogens and toxins in a biological sample for research use; nucleic acid sequencers for scientific purposes
(4) Medical devices for the qualitative detection of antibodies in human specimens collected as plasma or dried blood spots; polymerase chain reaction (PCR) tests for the detection of viruses in humans
09 - Appareils et instruments scientifiques et électriques
Produits et services
Computer software for use in the field of healthcare; computer software for medical and diagnostic purposes; computer software for the provision of automated diagnostic laboratory processes; computer software for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management; computer systems and software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes..
Provided is a component abnormality detecting system for detecting an abnormality of a component of a liquid transport system that sucks in and discharges a liquid to and from a sample inspection sensor of an automated analyzing device, the component abnormality detecting system comprising a storage device for storing data of an electrical signal output by the sensor, and a processing device for processing the data recorded in the storage device, wherein the processing device detects an abnormality of a component of the liquid transport system on the basis of the electrical signal.
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G01N 35/08 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant un courant d'échantillons discrets circulant dans une canalisation, p.ex. analyse à injection dans un écoulement
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
(1) Chemicals, biological substances and biochemicals used in science and research; in-vitro diagnostic reagents for scientific and research purposes; chemical additives, enzymes, reagents, organisms and proteins for use in science, research and industry; solutions and reagents for the accuracy checking of test results; solutions and reagents for the calibration and function control of apparatus.
(2) Chemical, biochemical and biological preparations for medical purposes; in-vitro diagnostic preparations for medical and diagnostic purposes; reagents for in-vitro laboratory tests for medical purposes. (1) Scientific and technological services and research and design relating thereto; industrial analysis and research services; consultancy, research and development in the fields of science, technology, IT; development of a database in the field of science, research, medicine and diagnostics.
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
(1) Scientific, electric, optical, measuring and checking apparatus and instruments included in this class, computer-aided and biotechnological analysis apparatus and installations constructed therefrom included in this class.
(2) Surgical, medical, dental and veterinary instruments and apparatus, medical, biotechnological and pharmaceutical analysis apparatus and installations constructed therefrom included in this class.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biochemical and biological reagents for medical and diagnostic purposes; diagnostic reagents for clinical, medical, and diagnostic purposes, loaded into laboratory test sample cards used for microbiological testing and identification; diagnostic test kits for clinical and medical diagnostic purposes consisting primarily of diagnostic reagents for use in disease testing; medical diagnostic test media in the form of a self-sampling test card for performing a HIV screening test Downloadable software in the nature of a mobile application and information platform for ordering medical diagnostic tests and tracking and storing medical information about an individual's diagnosis related to infectious disease; downloadable computer application software for use with mobile phones that enables users to access personal health summaries, laboratory test results, and health care resources Scientific and technological services, namely, research and design in the field of healthcare and providing scientific consultation and information relating thereto; platform as a service (PAAS) featuring computer software platforms for providing medical and scientific research information in the field of home screening for key indicators of infectious diseases; providing temporary use of online non-downloadable software for ordering diagnostic tests, tracking and storing medical information about an individual's diagnosis related to infectious diseases
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes].
(2) Medical apparatus and instruments; diagnostic apparatus for medical purposes; apparatus for carrying-out diagnostic tests for medical purposes; testing apparatus for medical purposes.
pRR0000p0000p0iiiii, a statistical parameter derived from a linear regression of the plurality of past eGFR values; and applying a machine-learning model to the input data to generate an output indicating the likelihood of kidney failure within the given amount of time Δt. Corresponding training methods and systems are also provided.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Chemical preparations for medical purposes; biological preparations for medical purposes; biochemical preparations for medical use; in vitro diagnostic preparations for medical use; diagnostic reagents for medical use; reagents for in-vitro laboratory use [for medical purposes].
(2) Medical apparatus and instruments; diagnostic apparatus for medical purposes; apparatus for carrying-out diagnostic tests for medical purposes; testing apparatus for medical purposes.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Downloadable computer software for use in the field of in vitro diagnostics; downloadable computer programs for use with blood gas analyzers for medical purposes; downloadable computer software featuring algorithms for laboratory test data analysis; downloadable computer software having processing algorithm used to measuring, collecting, analyzing, visualizing, recalculating, converting, extracting, reporting, storing and transmitting data from biological information for diagnostic purposes Design and development of software for use in the field of medical diagnostics; providing temporary use of non-downloadable computer software featuring algorithms for laboratory test data analysis; providing temporary use of non-downloadable computer software for viewing, analyzing, managing, reporting, and archiving data for use in the field of medicine, medical research and clinical research; design, development, and implementation of software for transforming raw data into actionable information for effective decision making in the field of healthcare organizations and solutions; design and development of medical diagnostic apparatus for blood gas analysis; maintenance of computer software for use in the field of medical diagnostics Conducting clinical trials; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical services in the field of blood gas analysis
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Business data collection and compilation of statistical
information into computer databases in the field of medicine
and healthcare; compiling scientific and/or clinical data,
in particular patient data; computer-based updating and
maintenance of data in databases, all in the pharmaceutical
and healthcare sector. Education; providing of training; medical courses; training
and tuition in connection with medical and medical
technology instruments, apparatus, equipment and methods;
arranging of conferences in the field of medicine; providing
educational materials and information in the field of health
and medicine. Scientific and technological services and research and
design relating thereto; industrial analysis, industrial
research and industrial design services; quality control and
authentication services; design and development of computer
hardware and software; technical remote monitoring of
laboratory apparatus and instruments and remote maintenance
of computer software in the field of pathology; application
service provider (ASP) services namely hosting computer
software for use in viewing, analyzing, managing, reporting
and archiving of digital images for use in the field of
pathology; software as a service (SaaS) services featuring
software for providing a remotely accessible image
management and viewing system for medical personnel;
providing web-based, non-downloadable software for use in
the medical imaging field, namely, pathology, microscopy,
histology; providing temporary use of non-downloadable
computer software for viewing, analyzing, managing,
reporting and archiving of digital images for use in the
field of pathology; providing web-based, non-downloadable
laboratory information management and workflow software.
87.
METHOD FOR OPERATING LABORATORY SYSTEM AND LABORATORY SYSTEM
A method for operating a laboratory system is disclosed, comprising providing a laboratory system having a plurality of sample containers (1) configured to contain a sample to be processed for at least one of pre-analysis and analysis in the laboratory system; a plurality of laboratory devices (2; 3; 4; 6) providing for a plurality of target devices each configured to handle one or more sample containers from the plurality of sample containers (1), the one or more sample containers being assigned for handling to the target device in operation of the laboratory system; and a control device (5) configured to at least control assignment of the plurality of sample containers (1) to the plurality of target devices; and assigning the plurality of sample containers (1) to the plurality of target devices in operation of the laboratory system. The assigning comprises: determining a target device workload state for each of the plurality of target devices, the target device workload state being in a range between a first range limit indicative of a first capacity for handling sample containers and a second range limit indicative a second capacity for handling sample containers, the second capacity being a higher capacity than the first capacity for handling sample containers, and determined according to a metric being proportional to a resource target device state indicative of a present number of sample containers assigned to the target device, and a power of an output flow of the target device, the output flow being indicative of output of sample containers per time by the target device; assigning the plurality of sample containers (1) to the plurality of target devices according to the target device workload states; and providing the plurality of sample containers (1) to the plurality of target devices for handling according to the assignment. Furthermore, a laboratory system is provided.
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p.ex. pour des analyses d’échantillon de patient
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet
G05B 19/042 - Commande à programme autre que la commande numérique, c.à d. dans des automatismes à séquence ou dans des automates à logique utilisant des processeurs numériques
G05B 19/418 - Commande totale d'usine, c.à d. commande centralisée de plusieurs machines, p.ex. commande numérique directe ou distribuée (DNC), systèmes d'ateliers flexibles (FMS), systèmes de fabrication intégrés (IMS), productique (CIM)
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santé; TIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p.ex. pour la gestion du personnel hospitalier ou de salles d’opération
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
(1) Software programmes for medical purposes; data processing devices for medical purposes.
(2) Medical apparatus for the analysis and evaluation of in vitro diagnostic tests; medical apparatus for the detection of substances in the urine; dispensers for taking up and selecting of reagent carriers for medical purposes.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
(1) Biochemical reagents used for non-medical purposes; buffer solutions for scientific purposes; chemical reagents for molecular biology, other than for medical or veterinary use.
90.
A COMPOSITION FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST VIA MASS SPECTROMETRY MEASUREMENTS
The present invention relates to a composition for determining at least one analyte of interest via Mass Spectrometry measurements and uses thereof, a kit and the use thereof, a method of determining the level of at least one analyte of interest in an obtained sample, a sampling tube for collecting a patient sample, an analyzer as well as the use of dialkyl sulfide as an additive in a formulation of β-lactam antibiotic analyte for preventing oxidation.
G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques
91.
DERIVATIZATION OF COMPOUNDS IN PATIENT SAMPLES FOR THERAPEUTIC DRUG MONITORING (TDM)
The present invention relates to a method of determining the level of at least one analyte of interest, sampling tubes for collecting a patient sample, the use of nucleophilic derivatization reagents, an analyzer as well as kits.
G01N 33/94 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des narcotiques
The invention relates to a laboratory apparatus (1), wherein the laboratory apparatus (1) comprises, - a housing (2), wherein the housing (2) comprises a through-opening (3), wherein the through-opening (3) is adapted for passing through it a transport device (4) for transporting laboratory sample containers (5) in and/or out of the housing (2), and - a cover (6), wherein the cover (6) comprises at least two ring segments (7a, 7b), wherein the ring segments (7a, 7b) are adjustable to each other between a distant adjustment (da) with at least one distance (Dla, Dlb) in between ends (7aE, 7bE) of the ring segments (7a, 7b) for arranging them around the passed through transport device (4) and a near adjustment (na) with less or no distance in between the ends (7aE, 7bE) of the ring segments (7a, 7b) for surrounding the passed through transport device (4), and wherein the cover (6) in the near adjustment (na) is adapted to cover a part (3f) of the through-opening (3) left free by the passed through transport device (4), - wherein the laboratory apparatus (1) is a pre-analytical, analytical, and/or post-analytical laboratory apparatus (1'), in particular a sorting module (1").
The present invention relates to methods to improve detection of amplification products from Loop-mediated Amplification (LAMP) reactions by the use of nucleotide analogs that form duplex structures that nucleic acid polymerase enzymes do not recognize efficiently.
A computer-implemented method of differentiating between lymphoid blast cells and myeloid blast cells comprises: receiving (S30) a digital image containing one or more blast cells; applying (S34) a parametric model classifier (412) to one or more portions of the digital image each containing a respective blast cell, the parametric model (416) configured to generate an output (S38) indicative of whether each blast cell is a lymphoid blast cell or a myeloid blast cell. Computer- implemented methods of training a parametric model (416) are also provided, as well as a clinical decision support system (400) relying on the computer-implemented method of classifying blast cells.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
95.
MODIFIED ANTIBODY FOR SITE-SPECIFIC CONJUGATION AND ITS DIAGNOSTIC USE
The present invention relates to a modified antibody comprising a heavy chain and a light chain, wherein the antibody is modified to include in one or more of its immunoglobulin polypeptide chains one or more first recognition site(s) for the transglutaminase from Kutzneria albida (KalbTG) or a functionally active variant thereof. The one or more first recognition site(s) are introduced at one or more selected position(s) within an antibody's heavy chain and/or an antibody's light chain. The invention further relates to one or more nucleic acid(s) encoding an immunoglobulin polypeptide chain including the one or more recognition site(s), a site-specifically conjugated antibody comprising the modified antibody and one or more labelling domain(s) covalently attached to one or more first recognition sites, a kit for producing the conjugated antibody, a method of specifically labelling the modified antibody by way of site-specific conjugation, the use of the modified antibody for producing a specifically site-specifically conjugated antibody, a method of detecting a target in a sample and the use of the site-specifically conjugated antibody in the detection of a target and/or in the diagnosis.
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p.ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/00 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux
A method of determining the concentration of at least one analyte in a sample (112) is proposed. The method comprises: i. providing at least one sensor device (110), the sensor device (110) comprising - at least one field effect transistor (114) having at least one source electrode (116), at least one drain electrode (118) and at least one gate electrode (120), • - at least one sensing electrode (132) configured for being in contact with the sample (112), the sensing electrode (132) being at least one of electrically connected to the gate electrode (120) of the field effect transistor (114) or integrated into the gate electrode (120) of the field effect transistor (114), and • - at least one control device (146), the control device (146) being configured for applying operation parameters to the field effect transistor (114) and for monitoring at least one signal value with the field effect transistor (114); • ii. at least one parameter selection step comprising selecting a set of operation parameters of the field effect transistor (114) for at least one subsequent measurement step, the parameter selection step comprising performing a plurality of evaluation measurements with the field effect transistor (114) by using various sets of operation parameter candidates and by selecting the set of operation parameters in accordance with at least one optimization criterion monitored during the evaluation measurements; and • iii. at least one measurement step comprising detecting the concentration of the analyte by applying the set of operation parameters selected in step ii. to the field effect transistor (114) and by determining at least one signal value with the field effect transistor (114). Further, a sensor device (110) for determining the concentration of at least one analyte in a sample (112) is proposed.
Automated methods for genotyping melting curves are described. Melting curves are processed and difference matrices are compiled based on the processed matrices. The difference matrices are used to compile a cluster matrix and the cluster matrix is filtered to determine clusters that are used for genotyping the melting curves.
The invention relates to a laboratory sample container carrier handling apparatus (1) comprising a revolving device (2) and a guiding surface (S), wherein an entry segment (EP) of the guiding surface (S) is adapted to smoothly receive a laboratory sample container carrier (3). The invention further relates to a laboratory automation system (100) comprising such a laboratory sample container carrier handling apparatus (1) and to a use of such a laboratory sample container carrier handling apparatus (1) for handling a laboratory sample container carrier (3) in, in particular such, a laboratory automation system (100).
G01N 35/04 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes ; Manipulation de matériaux à cet effet en utilisant une série de récipients à échantillons déplacés par un transporteur passant devant un ou plusieurs postes de traitement ou d'analyse - Détails du transporteur
99.
A NOVEL ANTIBODY FOR DETECTION OF AMYLOID BETA 42 (AΒ42)
The present invention relates to a monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 with advantageous features for Aß42 detection in vitro using immunoassays. Also provided is a polynucleotide or a set of polynucleotides encoding the same and a vector comprising said polynucleotide(s). Further provided is a host cell comprising the polynucleotide(s) and a corresponding production process using this host cell. Also provided herein are uses and methods employing the monoclonal antibody or an antigen-binding fragment thereof specifically binding to Aß42 as provided herein.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
09 - Appareils et instruments scientifiques et électriques
35 - Publicité; Affaires commerciales
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Software for use in the field of medicine, medical research
and clinical research; medical software for the field of
health IT and eHealth; software for use in healthcare
information management; downloadable computer databases
containing information in the field of medicine;
downloadable software for accessing, organizing,
interpreting and analyzing information from databases in the
medical field; computer databases, in particular computer
databases containing information about clinical, molecular,
scientific and patient specific data; computer software for
authorizing access to medical databases, in particular
application software, interface software, software drives,
data communication software and interactive computer
software; downloadable cloud computing software. Compiling scientific and/or clinical data, in particular
patient data; compiling scientific and/or statistical data,
in particular clinical data, namely patient data and/or data
from clinical studies; computer-based updating and
maintenance of data in databases, all in the pharmaceutical
and/or healthcare sector; electronic data collection and
compilation of statistical information into computer
databases in the field of medicine and healthcare; analyzing
and compiling business data for innovative healthcare
solutions. Scientific and technological services and research and
design relating thereto; design and development of computer
hardware and software; hosting services and software as a
service [saas] and rental of software; it consultancy and
information; providing temporary use of non-downloadable
computer software for viewing, analyzing, managing,
reporting, and archiving digital images for use in the field
of medicine, medical research and clinical research;
application service provider [asp] services, namely,
providing online non-downloadable software for use in the
field of medicine; providing virtual computer systems
through cloud computing; development of non-downloadable
online computer portal for the storage of scientific data;
electronic storage of medical data and information for
physicians and healthcare professionals.
